Versor Investments LP Has $350,000 Stock Position in Option Care Health, Inc. $OPCH

Versor Investments LP lessened its position in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 68.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 12,600 shares of the company’s stock after selling 26,964 shares during the quarter. Versor Investments LP’s holdings in Option Care Health were worth $350,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bryce Point Capital LLC bought a new stake in shares of Option Care Health in the 3rd quarter valued at $687,000. Johnson Investment Counsel Inc. lifted its holdings in Option Care Health by 25.5% in the third quarter. Johnson Investment Counsel Inc. now owns 110,992 shares of the company’s stock valued at $3,081,000 after buying an additional 22,536 shares during the period. Oppenheimer Asset Management Inc. boosted its position in Option Care Health by 23.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 55,429 shares of the company’s stock valued at $1,539,000 after acquiring an additional 10,512 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in Option Care Health by 987.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,414 shares of the company’s stock worth $39,000 after acquiring an additional 1,284 shares during the period. Finally, Cornerstone Planning Group LLC grew its holdings in Option Care Health by 7,621.4% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock worth $30,000 after acquiring an additional 1,067 shares during the period. Institutional investors and hedge funds own 98.05% of the company’s stock.

Option Care Health Stock Performance

NASDAQ OPCH opened at $35.42 on Friday. The company has a market cap of $5.62 billion, a P/E ratio of 28.11, a PEG ratio of 2.06 and a beta of 0.84. The company has a fifty day simple moving average of $33.61 and a 200 day simple moving average of $30.17. The company has a current ratio of 1.56, a quick ratio of 1.05 and a debt-to-equity ratio of 0.85. Option Care Health, Inc. has a 12-month low of $24.24 and a 12-month high of $36.80.

Analysts Set New Price Targets

OPCH has been the topic of several research analyst reports. National Bank Financial set a $37.00 target price on Option Care Health in a research report on Tuesday, January 27th. Barrington Research boosted their price target on Option Care Health from $38.00 to $42.00 and gave the company an “outperform” rating in a research note on Friday, January 16th. Stephens raised shares of Option Care Health to a “strong-buy” rating in a research report on Thursday, December 11th. Bank of America boosted their target price on shares of Option Care Health from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Finally, Morgan Stanley raised their price target on shares of Option Care Health from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.46.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.